What is your second line therapy for PDL1 negative metastatic squamous esophageal cancer who did not receive a checkpoint inhibitor in first line setting?
Would you use nivolumab or a taxane? Is the data from the ATTRACTION-3 trial with an all-Asian patient population applicable to practice to the US population?
Answer from: Medical Oncologist at Academic Institution
I would not personally consider immunotherapy in any context for such a patient. For the purpose of answering this question, I assume that a "PD-L1 negative" tumor refers to a PD-L1 TPS 0% and CPS 0 tumor.As a quick reminder, the 2 relevant studies in the US for 1st-line immunotherapy in ESCC patien...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Short Answer: Nivolumab. Let's first discuss the ATTRACTION-3 trial in detail. This was a multicenter randomized open-label trial in Denmark, Germany, Italy, Japan, South Korea, Taiwan, the UK, and the USA but 96% are identified as Asian in the demographics. Patients who were refractory o...
Comments
Medical Oncologist at St Louis Cancer Care LLP
Excellent point, although I have not had much succ...
Excellent point, although I have not had much succ...
Answer from: Medical Oncologist at Community Practice
A meta-analysis, involving five randomized controlled trials with a total of 1,970 patients with advanced ESCC patients, compared second line conventional chemotherapy to second-line PD-1 inhibitors (987 patients on PD-1 inhibitors and 983 on chemotherapy). (Zhu et al., PMID 34758782) The OS (h...